BACTEROMETRICS

Bioremediation of toxic metals and radionuclides using naturally evolved bacteria capable of intra-cellular reduction without oxidative stress

 Coordinatore COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Dr.
Nome: Catherine
Cognome: Berthomieu
Email: send email
Telefono: 33442254384
Fax: 33442252625

 Nazionalità Coordinatore France [FR]
 Totale costo 239˙736 €
 EC contributo 239˙736 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2007-4-1-IOF
 Funding Scheme MC-IOF
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-05-01   -   2011-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Dr.
Nome: Catherine
Cognome: Berthomieu
Email: send email
Telefono: 33442254384
Fax: 33442252625

FR (PARIS 15) coordinator 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

re    metal    evolved    oxygen    uranyl    sites    pathway    metals    bacterial    transfer    radionuclides    chrr    bioremediation    involves    cellular    species    waste    cells    toxic    bacteria    safe    naturally    oxidation   

 Obiettivo del progetto (Objective)

'Most toxic metals and radionuclides can be naturally rendered insoluble-immobile by bacterial reduction, which may be exploited for bioremediation purposes at waste repository sites. Some bacteria (e.g. iron or sulphate respirers) are receiving intense attention as their envelope-located electron transport chain can carry out such reductions. However, this process is subject to inhibition by nitrate and oxygen, usually present at waste sites. It also involves 1 e- transfer reactions generating reactive oxygen species which poison the cells and hamper remediation, and the reduced species are released outside the cells, where re-oxidation may occur rapidly. An alternative 'safe' bacterial pathway for reduction of metals-radionuclides has been discovered recently at the host laboratory (Dr. AC Matin). It involves proteins from the widely distributed ChrR enzyme family, performing 2 e- (4 e-) transfer processes strongly reducing oxidative stress, and leads to sequestering of reduced species. Strengthening this pathway should lessen metal toxicity and increase bioremediation capabilities. The objectives of this multidisciplinary project are (1) to assess this reduction process in bioreactors simulating waste sites conditions, using an engineered strain producing a highly improved ChrR, by analysing the oxidation state and distribution of reduced products; (2) as minor mutations of ChrR led to its increased efficiency, to test the hypothesis that improved ChrR activity is naturally present at US waste sites, where bacteria have been exposed to metals for over 50 years; (3) to test if the intra-cellular reduced products are indeed less amenable to re-oxidation than extra-cellular ones; and (4) to use the skills gained for the identification of new cytoplasmic enzymes with safe metal reduction mechanisms in uranyl-rich soils from Bessines (France), where bacterial communities with effective means of safe enzymatic reduction of uranyl are likely to have naturally evolved.'

Introduzione (Teaser)

Research into bioremediation of toxic pollutants is now making use of microbes that have evolved and survived on waste sites for more than half a century.

Altri progetti dello stesso programma (FP7-PEOPLE)

EMCHAHE (2013)

"EARLY MEDIEVAL CHURCHES: HISTORY, ARCHAEOLOGY AND HERITAGE"

Read More  

MALGENEXPRESSION (2008)

The role of a nuclear expression site in the regulation of virulence genes in malaria parasites

Read More  

RECURRENT GLIOMA TX (2013)

Phase I trial in recurrent high-grade glioma: High-dose vorinostat with concurrent hypofractionated radiation therapy

Read More